Highest-materiality recent filing
ICU Medical Q1 GAAP net income $30.1M vs loss a year ago; organic revenue up 1%
GAAP revenue $530.2M, down 12% YoY due to IV Solutions divestiture; non-GAAP organic revenue up 1%.
ICU Medical Q4: revenue $540.7M (-14% YoY), GAAP loss $(0.64)/share, adj EPS $1.91
Revenue $540.7M vs $629.8M in Q4 2024, down 14.1% YoY.
ICU Medical Q3 revenue down 8.8% YoY; adjusted EPS improves to $2.03
Q3 revenue $537M vs $589M YoY; GAAP net loss narrowed to $3.4M from $33M.
ICU Medical Q2 revenue down 8% to $549M, but GAAP net income of $35.3M vs year-ago loss
Revenue $548.9M vs $596.5M YoY; GAAP gross margin improved to 38% from 35%.
ICU Medical Q1 revenue up 7% to $605M; adjusted EPS $1.72 vs $0.96
Revenue $604.7M, up 6.7% YoY from $566.7M.
ICU Medical Q4 2024 revenue up 7% to $629.8M; adj. EPS $2.11 vs $1.57
Revenue $629.8M (+7% YoY); GAAP gross margin improved to 36.1% from 29.2%.
ICU Medical Q3 2024 revenue up 6.5% to $589.1M; GAAP net loss $33M, adj EPS $1.59
Revenue $589.1M vs $553.3M YoY; GAAP gross margin improved to 34.8% from 33.2%.
ICU Medical appoints Daniel Woolson as President, effective Sept. 30, 2024
Daniel Woolson, 48, appointed President of ICU Medical, effective immediately on Sept. 30, 2024.
Revenue $596.5M up 8.6% YoY from $549.3M; GAAP gross margin 35% unchanged.
ICU Medical Q1 GAAP EPS $(1.63) loss, revenue flat at $566.7M
Revenue $566.7M, down slightly from $568.6M YoY; GAAP net loss $(39.5)M vs $(9.8)M.
ICU Medical Q4 revenue up slightly but net loss widens; provides FY2024 guidance
Revenue $587.9M in Q4 2023, up 1.7% YoY from $578.0M.
ICU Medical Q2 revenue $549.3M (-2% YoY); adjusted EPS $1.88 vs $1.37; narrows FY23 guidance
Revenue $549.3M vs $561.0M YoY; GAAP gross margin improved to 35% from 30%.
ICU Medical Q1 revenue up 5% to $568.6M; GAAP loss narrows to $(0.41) from $(1.61)
Revenue $568.6M vs $543.1M YoY; GAAP gross margin 34% vs 31%.
ICU Medical Q4 2022 revenue $578M, GAAP net loss $15.5M, provides FY23 guidance
Revenue $578.0M vs $340.5M YoY; GAAP net loss $(15.5)M ($(0.65)/diluted) vs net income $19.9M ($0.91) in Q4 2021.
ICU Medical Q3 2022 revenue $597.9M; GAAP loss $(0.55)/share; adj EPS $1.75
Revenue $597.9M vs $336.1M YoY (+78%); GAAP net loss $(13.2)M ($(0.55)/diluted share).
ICU Medical Q2 revenue $561M; GAAP net loss $7.5M, adj EPS $1.37; updates FY guidance
Revenue $561.0M vs $321.7M YoY; GAAP net loss $(7.5M) vs income $28.4M.
ICU Medical Q1 revenue $543M, GAAP net loss $38.1M, adjusted EPS $1.82
Revenue $543.1M, up 71% from $318.0M in Q1 2021.
ICU Medical files Smiths Medical FY2021 audited financials; operating profit down 88% to $16M
Smiths Medical revenue $1,153M in FY2021, flat vs $1,159M prior year.
ICU Medical completes acquisition of Smiths Medical for $1.85B cash + stock
Paid $1.85B cash and issued 2.5M shares of ICUI common stock; up to $100M additional contingent cash.
ICU Medical Q3 revenue $336.1M (+5.5% YoY); adj. EPS $2.07 vs $1.90
Revenue $336.1M, up from $318.6M in Q3 2020.
ICU Medical enters binding agreement to acquire Smiths Medical after put option exercised
Seller exercised put option on Sep 27, 2021, triggering binding purchase agreement for Smiths Medical.
ICU Medical to acquire Smiths Medical for $2.35B in cash and stock; expected close H1 2022
Total consideration: $1.85B cash, 2.5M ICUI shares (~$500M), plus up to $100M earn-out based on stock price.
ICU Medical wins arbitration; Pfizer not entitled to up to $225M earn-out from 2017 Hospira deal
Arbitrator ruled on August 7, 2021 that performance targets for HIS earn-out liability were not met.
ICU Medical Q2 revenue $321.7M (+6% YoY); adj. EPS $1.88 vs $1.65
GAAP net income $28.4M ($1.31 diluted EPS) vs $18.9M ($0.88) a year ago.
On September 30, 2024, the Board of Directors of ICU Medical, Inc. (the “Company”) appointed Mr. Daniel Woolson, 48, as President of the Company, effective immediately.
On February 28, 2024, Mr. William Seeger notified the board of directors (the “Board”) of ICU Medical, Inc. (the “Company”) that he will retire from the board of directors of Smiths Group plc (“Smiths”) on May 31, 2024 and, in anticipation of his retirement, tendered his resignation from the Company Board and a member of the Audit and Compliance Committee of the Company Board as Smiths’ nominated director, effective immediately.
On February 16, 2022, Kevin McGrody, age 63, informed ICU Medical, Inc. (the “Company”) of his intention to retire as Chief Accounting Officer of the Company effective March 18, 2022.
appointed William Seeger to serve as a director of the Company, effective immediately.
On December 31, 2021, Robert S. Swinney notified ICU Medical, Inc. (the “Company”) of his resignation, effective December 31, 2021 from the Company’s Board of Directors (the “Board”) in accordance with the Board’s retirement policy after 24 years of service.
On December 31, 2021, the Board elected Ms. Kolleen Kennedy as a new director of the Company, effective December 31, 2021.
On July 1, 2021, the Board of Directors (the “Board”) of the Company elected Ms. Laurie Hernandez as the new director of the Company, effective July 1, 2021.
Max materiality 0.90 · Median 0.70 · Most common event earnings